1. Home
  2. AISP vs EQ Comparison

AISP vs EQ Comparison

Compare AISP & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Airship AI Holdings Inc.

AISP

Airship AI Holdings Inc.

HOLD

Current Price

$2.53

Market Cap

77.7M

Sector

Finance

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$1.98

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AISP
EQ
Founded
2006
2017
Country
United States
United States
Employees
63
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.7M
64.5M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
AISP
EQ
Price
$2.53
$1.98
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
423.4K
396.7K
Earning Date
05-14-2026
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,095,000.00
Revenue This Year
$222.88
N/A
Revenue Next Year
$5.36
N/A
P/E Ratio
$3.18
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.03
$0.29
52 Week High
$7.20
$2.70

Technical Indicators

Market Signals
Indicator
AISP
EQ
Relative Strength Index (RSI) 56.33 52.78
Support Level $2.36 $1.22
Resistance Level $2.85 $2.13
Average True Range (ATR) 0.15 0.20
MACD 0.05 -0.01
Stochastic Oscillator 93.27 69.30

Price Performance

Historical Comparison
AISP
EQ

About AISP Airship AI Holdings Inc.

Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture. Airship AI's software allows customers to view structured data both in real-time as well as to conduct searches on the structured data at a later point in time.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: